Introduction
============

MAPK/ERK (mitogen-activated protein kinases/extracellular signal-regulated kinases) is a conserved signaling pathway, which in response to a plethora of intracellular and extracellular signals, such as cytokines, mitogens, growth factors, hormones, and neurotransmitters, elicits changes in cellular gene-expression programs ([@B35]; [@B57]). In the brain, activation of MAPK/ERK in response to excitatory glutamatergic signaling has been linked to regulation of synaptic plasticity, learning, and memory ([@B14]; [@B63]; [@B35]; [@B57]). Indeed, LTP of excitatory synaptic transmission, mainly in the mammalian hippocampus, requires MAPK/ERK activity ([@B33]; [@B35]). Accordingly, MAPK/ERK inhibition impairs learning and hippocampal spatial memory ([@B1]) and fear conditioning in rodents ([@B53]).

Downstream of MAPK/ERK, the MNK1/2 kinases regulate mRNA translation ([@B32]) mainly by phosphorylating eIF4E on Ser209 ([@B16]; [@B31]). eIF4E binds to the mRNA 5′ cap, and together with eIF4G (scaffolding protein) and eIF4A (mRNA helicase), form the eIF4F complex, promoting translation initiation ([@B27]). eIF4E stimulates the translation of a subset of mRNAs ("eIF4E-sensitive"), without upregulating global protein synthesis ([@B27]). eIF4E, apart from its primary cap binding function, also promotes mRNA restructuring and initiation by stimulating eIF4A helicase activity ([@B15]). Thus, eIF4E-sensitive mRNAs contain long and highly structured 5′-untranslated regions (UTRs, e.g., proto-oncogenes and growth factors), which require elevated helicase activity for their translation ([@B56]).

Most of the current literature posits that eIF4E phosphorylation promotes mRNA translation ([@B46]; [@B38]; [@B45]; [@B4]). It was also suggested that eIF4E phosphorylation is not required for translation ([@B42]) or that it decreases cap-dependent translation ([@B36]). Several studies identified phospho-eIF4E-sensitive mRNAs in cancer models ([@B19]; [@B37]; [@B50]); however, in brain, only a small subset was revealed. In the hippocampus, phospho-eIF4E regulates the translation of *Mmp9* ([@B22]; [@B21]), while in the suprachiasmatic nucleus, phospho-eIF4E controls the translation of *Per1/2* mRNAs ([@B6]). Interestingly, phospho-eIF4E is a master regulator of Type I IFN production, and thus of the antiviral response, by controlling the translation of *NFKBIA* mRNA (coding for IκBα protein; nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, α) ([@B25]). Ablation of phospho-eIF4E downregulates IκBα and activates the transcription factor NF-κB, which regulates cytokine production and antiviral responses ([@B25]). Whereas phospho-eIF4E has been implicated in the regulation of some brain functions ([@B22]; [@B6]), its precise role in the brain is yet to be elucidated. Little is also known about the subset of phospho-eIF4E-dependent mRNAs or about the regulatory mechanisms governing their translation in the brain.

Herein, we show that, in mice lacking eIF4E phosphorylation (*4Eki*), hippocampal long-term spatial and fear memory formation, and late LTP (L-LTP) are intact. Using unbiased ribosome profiling in *4Eki* brains, we identified reduced translation of mRNAs coding for extracellular matrix (ECM) proteins and pituitary hormones and, unexpectedly, increased translation of serotonin pathway and ribosomal protein mRNAs. This altered translational landscape in *4Eki* brain is accompanied by exaggerated inflammatory responses and reduced brain serotonin levels. Subsequently, we show that *4Eki* mice display depression-like behaviors, which are resistant to chronic treatment with the selective serotonin reuptake inhibitor (SSRI) antidepressant fluoxetine. We demonstrate a potential mechanism for phospho-eIF4E translational control in the brain, which is mediated by altered gamma IFN activated inhibitor of translation (GAIT)-dependent translation and reduced binding of eIF4A1 to the 5′mRNA cap. Together, these data establish a previously unidentified role for eIF4E phosphorylation in depression due to selective translation of a subset of mRNAs.

Materials and Methods
=====================

### 

#### Transgenic mice.

All procedures were in accordance with United Kingdom Home Office and Canadian Council on Animal Care regulations and were approved by the University of Edinburgh and McGill University. *eIF4E^Ser209Ala^* mice were previously described ([@B22]) and were maintained on the C57BL/6J background (backcrossed for \>10 generations). For most experiments, male mice 8--12 weeks of age were used (for slice electrophysiology 6- to 8-week-old males were used). Food and water were provided *ad libitum*, and mice were kept on a 12 h light/dark cycle. Pups were kept with their dams until weaning at postnatal day 21. After weaning, mice were group housed (maximum of 4 per cage) by sex. Cages were maintained in ventilated racks in temperature (20°C-21°C) and humidity (∼55%) controlled rooms, on a 12 h circadian cycle (7:00 AM to 7:00 PM light period). For all behavioral testing, mice were handled/habituated for 3--4 consecutive days before experimental testing. Fluoxetine hydrochloride (Sigma-Aldrich) or vehicle (saline) was injected at 10 mg/kg intraperitoneally for 21 d. Lipopolysaccharide (LPS, strain O111:B4; Sigma-Aldrich) or vehicle (saline) was injected at 5 mg/kg intraperitoneally and brains were collected 4 h later.

#### Morris Water Maze (MWM).

Mice were handled for 3 d before the experiment. Training in the pool (100-cm-diameter and 10-cm-diameter platform; water temperature was 24°C) consisted of three trials per day (20 min intertrial interval), where each mouse swam until it reached the hidden platform. Animals that did not find the platform after 60 s were gently guided to it and would remain there for 10 s before returning them to the cage. For the probe test, the platform was removed and animals could swim for 60 s. The swimming trajectory and velocity were monitored with a video tracking system (HVS Image).

#### Contextual fear conditioning (CFC).

Mice were handled for 3--4 d before the start of the experiment and then conditioned in the chamber: 2 min acclimatization to the context, followed by the unconditioned stimulus; one foot shock (0.5 mA, 4 s) followed by a 30 s interval, terminating with another identical foot shock. The mice remained in the chamber for an additional 1 min after the end of the last unconditioned stimulus, after which they were returned to their home cages. Contextual fear memory was assayed 24 h after training by reexposing the animals to the conditioning context for a 5 min period. During this period, the incidence of freezing (immobile except for respiration) was recorded (FreezeFrame, Coulbourn Instruments). Freezing behavior was analyzed by assigning at 5 s intervals as either freezing or not freezing. Data are expressed as the percentage of 5 s intervals scored as "freezing."

#### Forced Swim Test (FST).

Transparent glass cylinders (50 cm height × 20 cm diameter) were filled with tap water maintained at 25°C. The water depth was adjusted according to the size of the mouse, so that it could not touch the bottom of the container with its hind legs. Animals were tested for 6 min, while only the last 4 min were scored for immobility using a manual timer.

#### Tail Suspension Test (TST).

Each mouse was suspended within its own three-walled (white) rectangular compartment (55 cm height × 15 cm width × 11.5 cm depth) in the middle of an aluminum suspension bar using adhesive tape. The width and depth are sufficiently sized so that the mouse cannot touch the walls. The duration of the test is 5 min and immobility was manually scored with a timer.

#### Novelty Suppressed Feeding (NSF).

Mice were handled for 3 d and following 24 h food deprivation were placed in a 40 × 40 cm^2^ open field arena for 5 min. Weight loss was \<7%, and no difference was seen between genotypes. At the center of the arena, two food pellets were fixed on a Whatman paper covered circular platform (replaced between subjects) glued on a 10 m Petri dish, to stop mice from removing the pellets. Animals that did not consume the pellets within the testing period were assigned to a latency of 300 s. The latency to grab food with both limbs and commence eating was measured with a stopwatch, and animals were weighed before the start of the experiment.

#### Open Field Test (OF).

Mice were handled for 3--4 d and then allowed to freely explore a 40 × 40 cm^2^ open field arena for 10 min. A 20 × 20 cm center region was designated as the center square. Time in the center square and outside as well as total distance traveled were recorded.

#### Elevated Plus Maze (EPM).

Mice were handled for 3--4 d and then allowed to freely explore an EPM (50 cm from ground), with open (2) and closed (2) arms: 50 cm length × 10 cm width and 40 cm height for the walls of closed arms. Time spent in the closed and open arms over a period of 5 min was manually recorded using a handheld timer.

#### Extracellular field recordings.

Transverse hippocampal slices (400 μm) were prepared from wild-type (WT) or *4Eki* males (6--8 weeks old). Slices were then allowed to recover submerged for at least 1 h at 32°C in oxygenated ACSF containing 124 m[m]{.smallcaps} NaCl, 2.5 m[m]{.smallcaps} KCl, 1.25 m[m]{.smallcaps} NaH~2~PO~4~, 25 m[m]{.smallcaps} NaHCO~3~, 20 m[m]{.smallcaps} glucose, 1 m[m]{.smallcaps} MgCl~2~, and 2 m[m]{.smallcaps} CaCl~2~ before transferring to a recording chamber at 29°C--31°C, which was continuously perfused with ACSF. fEPSPs were recorded in CA1 stratum radiatum with glass electrodes (2--3 [m]{.smallcaps}Ω) filled with ACSF. Schaffer collateral fEPSPs were evoked with a twisted bipolar stimulating electrode placed in stratum radiatum proximal to CA3 region. All signals collected were analyzed using WinLTP program. Test pulses were adjusted to obtain 40%--50% maximal fEPSP, delivered every 30 s, and averaged over 1 min. Basal responses were measured 60 min before the LTP stimulus. For the induction of L-LTP, four 1 s trains of 100 Hz high-frequency stimulation were delivered with an intertrain interval of 5 min. The initial slopes of the fEPSPs were measured, and values were normalized to the averaged baseline slope value for each slice. Percentage of potentiation was calculated as the difference between averaged values for a 10 min period before the tetanus and the last 10 min of recording.

#### Immunoblotting.

Dissected brain tissue was homogenized in buffer B (50 m[m]{.smallcaps} MOPS/KOH, pH 7.4, 100 m[m]{.smallcaps} NaCl, 50 m[m]{.smallcaps} NaF, 2 m[m]{.smallcaps} EDTA, 2 m[m]{.smallcaps} EGTA, 1% NP-40, 7 m[m]{.smallcaps} β-mercaptoethanol) supplemented with protease and phosphatase inhibitors (Roche). Samples were incubated on ice for 15 min, with occasional vortexing, and cleared by centrifugation for 20 min at 16,000 × *g* at 4°C. The supernatant was used for Western blotting after the protein concentration of each sample was determined by measuring A280 absorbance on a NanoDrop (ThermoFisher Scientific). The 50 μg of protein per lane was prepared in SDS sample buffer (50 m[m]{.smallcaps} Tris, pH 6.8, 100 m[m]{.smallcaps} DTT, 2% SDS, 10% glycerol, 0.1% bromophenol blue), heated to 98°C for 5 min, and resolved on 10%--16% polyacrylamide gels. Proteins were transferred to 0.2 μm nitrocellulose membranes (Bio-Rad), blocked in 5% BSA in TBS-T (10 m[m]{.smallcaps} Tris, pH 7.6, 150 m[m]{.smallcaps} NaCl, 0.1% Tween 20) for 1 h at room temperature, incubated with primary antibodies overnight at 4°C and with secondary antibodies for 1 h at room temperature. Primary antibodies were diluted in 1% BSA in TBS-T containing 0.02% Na azide, and between incubations membranes were washed extensively in TBS-T. Blots were imaged using an Odyssey Imaging System (Li-COR Biosciences) at a resolution of 169 μm and quantified using the ImageStudio Software (Li-COR Biosciences). For quantitative Western blotting, the intensity of each protein band was measured in triplicate to minimize measuring variability. β-actin was used as a loading control. Data are shown as arbitrary units after normalization to control.

#### Antibodies.

The antibodies used for immunoblotting or immunofluorescence are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Details of antibodies used

  Protein                Host species   Supplier                    Catalog \#   Predicted kDa   WB or IF
  ---------------------- -------------- --------------------------- ------------ --------------- ---------------------
  β-actin                Mouse          Sigma-Aldrich               A5316        42              1:5000 WB
  eIF4A1                 Rabbit         Abcam                       ab31217      48              1:1000 WB
  eIF4E                  Mouse          Santa Cruz Biotechnology    sc-271480    29              1:1000 WB, 1:500 IF
  eIF4E phospho Ser209   Rabbit         Abcam                       ab76256      25              1:500 IF
  eIF4G1                 Rabbit         Cell Signaling Technology   2498         220             1:1000 WB
  RPL13A                 Rabbit         Cell Signaling Technology   2765         23              1:500 WB
  EPRS                   Rabbit         Abcam                       ab31531      163             1:1000 WB
  GAPDH                  Rabbit         Cell Signaling Technology   2118         37              1:1000 WB

#### Immunofluorescence and confocal imaging.

Mice were anesthetized and transcardially perfused with 4% PFA (Electron Microscopy Sciences) in PBS. The brain was immediately dissected from the skull, postfixed in 4% PFA in PBS overnight at 4°C, and cryopreserved in a solution of 30% sucrose in PBS for 48 h at 4°C. Each brain was embedded in a mixture (1:1) of OCT:30% sucrose, and 30 μm coronal sections were cut on a cryostat (Leica). Sections were stored at 4°C as floating sections in PBS with 0.02% Na azide, until used. Sections were then incubated in blocking solution (5% NGS; Cell Signaling Technology), 0.3% Triton X-100 (Sigma-Aldrich) in PBS for 1 h at room temperature, washed briefly in PBS, and incubated with primary antibodies overnight at 4°C and with secondary antibodies for 2 h at room temperature. The antibodies were diluted in 2% NGS, 0.1% Triton X-100 in PBS, and the sections were washed extensively in PBS between incubations. A nuclear counterstain was applied by incubating the sections for 5 min with DAPI solution (1 μg/ml; ThermoFisher Scientific). Sections were mounted on glass slides using PermaFluor Mounting Media (ThermoFisher Scientific), protected with a glass coverslip, and stored at 4°C in the dark. Images were collected on a Zeiss LSM800 confocal microscope.

#### Quantitative ELISA for cytokines and serotonin.

Forebrain tissue was homogenized in kit sample buffer (QiaMouse Inflammatory Cytokines, Generon Iba-1 or Chemokines Multi-Analyte ELISArray Kit, QIAGEN and Serotonin ELISA kit, Enzo Life Sciences) with ∼30 strokes in a glass Dounce homogenizer on ice. Lysates were centrifuged at 16,000 × *g* for 5 min, and the supernatant was used for the assay. Detection was performed as per each kit\'s guidelines. For both assays, 50 μg of total protein was analyzed per sample (measured by Bradford assay, Bio-Rad). Optical density values were converted to pg/mg of total protein using curves of OD versus kit standard cytokine concentrations. In brain tissue, we detected the following cytokines from the kit: IL1B, IL2, IL6, IL10, IFNγ and TNFα, and ionized calcium-binding adapter molecule-1 (Iba-1) and serotonin as pg/mg of tissue.

#### Ribosome profiling and bioinformatics analysis.

Flash-frozen forebrain tissue was pulverized using liquid nitrogen and then lysed in hypotonic buffer: 5 m[m]{.smallcaps} Tris-HCl, pH 7.5, 2.5 m[m]{.smallcaps} MgCl~2~, 1.5 m[m]{.smallcaps} KCl, 1× protease inhibitor mixture (EDTA-free), 100 μg/ml cycloheximide (Sigma-Aldrich), 2 m[m]{.smallcaps} DTT 0.5% (w/v) Triton X-100, and 0.5% (w/v) sodium deoxycholate, to isolate the polysomes with centrifugation (20,000 × *g*) at 4°C for 5 min. Ribosome profiling was performed as previously described ([@B30]), with minor modifications. Briefly, 500 μg of the lysed RNPs (forebrain tissue) was subjected to ribosome footprinting by RNase I treatment at 4°C for 45 min with gentle mixing. Monosomes were pelleted by ultracentrifugation in a 34% sucrose cushion at 70,000 RPM for 3 h, and RNA fragments were extracted twice with acid phenol, once with chloroform, and precipitated with isopropanol in the presence of NaOAc and GlycoBlue. Purified RNA was resolved on a denaturing 15% polyacrylamide urea gel, and the section corresponding to 28--32 nucleotides containing the ribosome footprints was excised, eluted, and precipitated by isopropanol; 100 μg of cytoplasmic RNA was used for mRNA-Seq analysis. Poly(A)^+^ mRNAs were purified using magnetic oligo-dT DynaBeads (Invitrogen) according to the manufacturer\'s instructions. Purified RNA was eluted from the beads and mixed with an equal volume of 2× alkaline fragmentation solution (2 m[m]{.smallcaps} EDTA, 10 m[m]{.smallcaps} Na~2~CO~3~, 90 m[m]{.smallcaps} NaHCO~3~, pH 9.2) and incubated for 20 min at 95°C. Fragmentation reactions were mixed with stop/precipitation solution (300 m[m]{.smallcaps} NaOAc, pH 5.5, and GlycoBlue), followed by isopropanol precipitation. Fragmented mRNA was size-selected on a denaturing 10% polyacrylamide urea gel, and the area corresponding to 35--50 nucleotides was excised, eluted, and precipitated with isopropanol. All samples were analyzed on a Bioanalyzer High Sensitivity DNA chip (Agilent Technologies) to confirm expected size range and quantity and sequenced on a HiSeq 2500 system (Illumina). Raw sequencing data were demultiplexed by the sequencing facility (Genome Quebec). Sequences were analyzed using a custom-developed bioinformatics pipeline adapted from [@B30]). Reads were adapter-trimmed using the FASTX toolkit, contaminant sequences (rRNA, tRNA) removed using bowtie, and reads aligned to a reference genome using STAR. Cufflinks was used to quantify reads and calculate reads per kilobase of transcript per million mapped reads (RPKM) for each transcript. Translational efficiency (TE) for each transcript was calculated by dividing RPKM values of the RPF libraries by RPKM values of the total RNA libraries. Changes in TE and transcription (mRNA RPKM) values were analyzed for predefined pairwise comparisons between experimental groups (for review, see [@B47]). First, averages were calculated for replicate TE/RPKM values of each treatment on a per-gene basis using the geometric mean. From these averages, two statistics were derived for each gene: (1) ratio, defined as the quotient of values for alternative treatment (e.g., knock-in) and base level treatment (e.g., WT); and (2) intensity, defined as the product of the aforementioned values. Data were ordered by increasing log~10~(Intensity). Along this ordered set of values, mean log~10~ (Intensity) as well as mean and SD of log~2~(Ratio) were calculated within a sliding window of 100 genes at steps of 50 genes. Each gene was assigned to the window with a mean log~10~ (Intensity) closest to the gene\'s log~10~(Intensity). A *z* score was then calculated for the *i*^th^ gene using its window\'s log~2~(Ratio) mean and SD as follows: A *p* value was derived from the *z* score of the *i*^th^ gene by treating the latter as a quantile of the standard normal distribution as follows: False-discovery rates (FDRs) were calculated from *p* values derived with the *z* score as in [@B49]). Genes with \<128 reads were discarded. Raw RNAseq data will be deposited to NCBI Gene Expression Omnibus.

#### Principal components analysis (PCA) and hierarchical clustering.

PCA was conducted with R package vegan version 2.4.4. Genes with undefined log2-transformed values (for RPKM = 0 or TE = 0) were excluded from the analysis. log~2~-transformed values of the remaining set of genes were standardized on a per-gene basis (scaled to mean = 0 and SD = 1). Euclidean distances of samples (replicates) were calculated from the same standardized log2-transformed gene data used in PCA. Hierarchical clustering based on the complete-linkage algorithm was performed on the distance matrix with R package stats version 3.4.2. Results were visualized as dendrograms below the corresponding PCA plot.

#### g:profiler analysis of mRNAs.

Functional enrichment analysis was performed using the g:Ghost package of g:profiler to assign gene ontology categories to ribosome profiling lists of differentially translated genes ([@B48]). Hierarchical filtering was used: best per parent group-strong. The probability threshold for all functional categories was set at 0.05, using correction for multiple testing with the g:SCS algorithm ([@B48]).

#### UTR sequence analysis.

UTR sequence analysis was performed using RegRNA ([@B29]). Motifs in 5′- and 3′-UTR were detected with default parameters; 652 downregulated, 52 upregulated, and 325 control mRNA UTRs were obtained from Biomart ENSEMBL ([@B60]) using the GRCm38.p5 version of the mouse genome. Length in BP and %GC content were calculated using free Python-based scripts (Multifastats; <https://github.com/davidrequena/multifastats>).

#### Cap column pulldown.

Forebrain tissue was dissected and lysates were prepared in the same way as for immunoblotting (see above); 500 μg of protein was incubated with 50 μl of m^7^GDP agarose (Jena Biosciences), in a total volume of 1 ml buffer C (50 m[m]{.smallcaps} MOPS-KOH, pH 7.4, 100 m[m]{.smallcaps} NaCl, 50 m[m]{.smallcaps} NaF, 0.5 m[m]{.smallcaps} EDTA, 0.5 m[m]{.smallcaps} EGTA, 7 m[m]{.smallcaps} β-mercaptoethanol, 0.5 m[m]{.smallcaps} PMSF, 1 m[m]{.smallcaps} Na~3~VO~4~, and 0.1 m[m]{.smallcaps} GTP), for 90 min at 4°C with rotation. The beads were washed three times in buffer C, and the cap-bound fraction was eluted in 50 μl of 2× SDS sample buffer with boiling at 70°C for 10 min.

#### Experimental design and statistical analysis.

Experimenters were blinded to the genotype during testing and scoring. All data are presented as mean ± SEM (error bars), and individual experimental points are depicted in column or bar graphs. Statistical significance was set a priori at 0.05. Fluoxetine treatment was randomized across cages (not all animals in one cage received the same treatment; vehicle or fluoxetine). No nested data were obtained in this study; we only collected one observation per research object. Details for statistical tests used were provided within figure legends or the relative methods description and summarized in [Table 2](#T2){ref-type="table"}. Data summaries and statistical analysis were performed using GraphPad Prism 6 and SPSS version 21 (IBM).

###### 

Statistical analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Test                                                                                          Mean ± SEM                                                                                              Significance and multiple comparisons        Parameter                                                                   *N*                                     Descriptive statistics                         Figure
  --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------------------------------------------------------------- --------------------------------------- ---------------------------------------------- -----------------------------
  Repeated-measures ANOVA, with Tukey\'s post hoc                                               WT: 28.404 ± 1.700                                                                                      Day: *p* \< 0.001                            Latency (s)                                                                 WT (7), 4Eki (8)                        Day: *F*~(4,68)~ = 39.900                      [1](#F1){ref-type="fig"}*B*

  4Eki: 27.630 ± 1.792                                                                          Genotype: *p* = 0.758                                                                                   Genotype: *F*~(1,17)~ = 0.098                                                                                                                                                                                   

  Day × Genotype: *p* = 0.668                                                                   Day × Genotype: *F*~(4,68)~ = 0.595                                                                                                                                                                                                                                                                                     

  Target quadrant:                                                                              Quadrant: *p* \< 0.001                                                                                  No. of platform crossings                    Day: *F*~(4,68)~ = 39.900                                                                                                                                          

  WT: 6.857 ± 0.519                                                                             Genotype: *p* = 0.960                                                                                   Genotype: *F*~(1,17)~ = 0.098                                                                                                                                                                                   

  4Eki: 6.500 ± 0.486                                                                           Quadrant × Genotype: *p* = 0.578                                                                        Day × Genotype: *F*~(4,68)~ = 0.595                                                                                                                                                                             

  Right quadrant:                                                                                                                                                                                                                                                                                                                                                                                                       

  WT: 3.857 ± 0.519                                                                                                                                                                                                                                                                                                                                                                                                     

  4Eki 3.375 ± 0.486                                                                                                                                                                                                                                                                                                                                                                                                    

  Opposite quadrant:                                                                                                                                                                                                                                                                                                                                                                                                    

  WT: 3.286 ± 0.519                                                                                                                                                                                                                                                                                                                                                                                                     

  4Eki: 3.250 ± 0.486                                                                                                                                                                                                                                                                                                                                                                                                   

  Left quadrant:                                                                                                                                                                                                                                                                                                                                                                                                        

  WT: 3.571 ± 0.519                                                                                                                                                                                                                                                                                                                                                                                                     

  4Eki: 4.375 ± 0.486                                                                                                                                                                                                                                                                                                                                                                                                   

  Target quadrant:                                                                              Quadrant: *p* \< 0.001                                                                                  Quadrant occupancy (%)                       Quadrant: *F*~(3,52)~ = 18.160                                                                                                                                     

  WT: 32.286 ± 1.922                                                                            Genotype: *p* = 0.946                                                                                   Genotype: *F*~(1,52)~ = 0.005                                                                                                                                                                                   

  4Eki: 33.625 ± 1.798                                                                          Quadrant × Genotype: *p* = 0.756                                                                        Quadrant × Genotype: *F*~(3,52)~ = 0.396                                                                                                                                                                        

  Right quadrant:                                                                                                                                                                                                                                                                                                                                                                                                       

  WT: 24.714 ± 1.922                                                                                                                                                                                                                                                                                                                                                                                                    

  4Eki: 23.00 ± 1.798                                                                                                                                                                                                                                                                                                                                                                                                   

  Opposite quadrant:                                                                                                                                                                                                                                                                                                                                                                                                    

  WT: 23.571 ± 1.922                                                                                                                                                                                                                                                                                                                                                                                                    

  4Eki: 22.250 ± 1.798                                                                                                                                                                                                                                                                                                                                                                                                  

  Left quadrant:                                                                                                                                                                                                                                                                                                                                                                                                        

  WT: 19.286 ± 1.922                                                                                                                                                                                                                                                                                                                                                                                                    

  4Eki: 20.625 ± 1.798                                                                                                                                                                                                                                                                                                                                                                                                  

  Student\'s *t* test                                                                           WT: 30.75 ± 6.35                                                                                        *p* = 0.077                                  Freezing (%)                                                                WT (8), 4Eki (8)                        Genotype: *F*~(1,19)~ = 0.088                  [1](#F1){ref-type="fig"}*C*

  4Eki: 3.57 ± 7.02                                                                                                                                                                                                                                                                                                                                                                                                     

  Student\'s *t* test                                                                           WT: 13.44 ± 4.337                                                                                       *p* = 0.968                                  \% potentiation                                                             WT (7), 4Eki (6)                        *t* = 3.551; df = 13                           [1](#F1){ref-type="fig"}*E*

  4Eki: 13.18 ± 4.911                                                                                                                                                                                                                                                                                                                                                                                                   

  One-way ANOVA with Tukey\'s post hoc                                                          Down: 247.0 ± 6.660                                                                                     Up versus down: *p* = 0.005                  5′-UTR length                                                               Down (651), up (52), control (325),     *F*~(3,53702)~ = 7.255C                        [2](#F2){ref-type="fig"}*D*

  Up: 138.0 ± 29.790                                                                            Control versus down: *p* \< 0.001                                                                                                                                                                                                                                                                                       

  Control: 188.0 ± 14.530                                                                       Whole genome versus down: *p* = 0.014                                                                                                                                                                                                                                                                                   

  Whole genome: 219.7 ± 1.008                                                                   Control versus up: *p* = 0.468                                                                                                                                                                                                                                                                                          

  Whole genome versus up: *p* = 0.0524                                                                                                                                                                                                                                                                                                                                                                                  

  Whole genome versus Control: *p* = 0.0645                                                                                                                                                                                                                                                                                                                                                                             

  Down: 59.38 ± 0.555                                                                           Up versus down: *p* = 0.663                                                                             5′-UTR GC % content                          *F*~(3,53310)~ = 2.018                                                                                                                                             

  Up: 61.46 ± 1.492                                                                             Control versus down: *p* = 0.453                                                                                                                                                                                                                                                                                        

  Control: 60.85 ± 0.602                                                                        Whole genome versus down: *p* \> 0.999                                                                                                                                                                                                                                                                                  

  Whole genome: 59.43 ± 0.052                                                                   Control versus up: *p* = 0.986                                                                                                                                                                                                                                                                                          

  Whole genome versus up: *p* = 0.611                                                                                                                                                                                                                                                                                                                                                                                   

  Whole genome versus Control: *p* = 0.141                                                                                                                                                                                                                                                                                                                                                                              

  Down: 1112 ± 89.52                                                                            Up versus down: *p* = 0.998                                                                             3′-UTR length                                *F*~(3,49949)~ = 2.146                                                                                                                                             

  Up: 1095 ± 150.6                                                                              Control versus down: *p* = 0.452                                                                                                                                                                                                                                                                                        

  Control: 1293 ± 91.93                                                                         Whole genome versus down: *p* = 0.998                                                                                                                                                                                                                                                                                   

  Whole genome: 1095 ± 6.326                                                                    Control versus up: *p* = 0.780                                                                                                                                                                                                                                                                                          

  Whole genome versus up: *p* \> 0.999                                                                                                                                                                                                                                                                                                                                                                                  

  Whole genome versus Control: *p* = 0.055                                                                                                                                                                                                                                                                                                                                                                              

  Down: 46.34 ± 0.534                                                                           Up versus down: *p* = 0.7808                                                                            3′-UTR GC % content                          *F*~(3,49949)~ = 1.963                                                                                                                                             

  Up: 45.07 ± 0.877                                                                             Control versus down: *p* = 0.214                                                                                                                                                                                                                                                                                        

  Control: 44.86 ± 0.458                                                                        Whole genome versus down: *p* = 0.073                                                                                                                                                                                                                                                                                   

  Whole genome: 44.91 ± 0.039                                                                   Control versus up: *p* = 0.998                                                                                                                                                                                                                                                                                          

  Whole genome versus up: *p* = 0.999                                                                                                                                                                                                                                                                                                                                                                                   

  Whole genome versus Control: *p* = 0.999                                                                                                                                                                                                                                                                                                                                                                              

  One-way ANOVA with Bonferroni\'s post hoc                                                     WTveh-IFNγ: 0.011 ± 0.001                                                                               WTveh-IFNγ versus WTlps-IFNγ: *p* = 0.003    Concentration (pg/mg protein)                                               WT (10), 4Eki (10)                      *F*~(3,36)~ = 52.02                            [3](#F3){ref-type="fig"}*A*

  WTlps-IFNγ: 0.024 ± 0.002                                                                     WTveh-IFNγ versus 4Ekiveh-IFNγ: *p* = 0.122                                                                                                                                                                                                                                                                             

  4Ekiveh-IFNγ: 0.019 ± 0.002                                                                   WTveh-IFNγ versus 4Ekilps-IFNγ: *p* \< 0.001                                                                                                                                                                                                                                                                            

  4Ekilps-IFNγ: 0.052 ± 0.003                                                                   WTlps-IFNγ versus 4Ekiveh-IFNγ: *p* \> 0.999                                                                                                                                                                                                                                                                            

  WTlps-IFNγ versus 4Ekilps-IFNγ: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                          

  4Ekiveh-IFNγ versus 4Ekilps-IFNγ: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                        

  WTveh-IL-2: 1.927 ± 0.064                                                                     WTveh-IL-2 versus WTlps-IL-2: *p* \< 0.001                                                              *F*~(3,36)~ = 266.7                                                                                                                                                                                             

  WTlps-IL-2: 7.412 ± 0.177                                                                     WTveh-IL-2 versus 4Ekiveh-IL-2: *p* \< 0.001                                                                                                                                                                                                                                                                            

  4Ekiveh-IL-2: 3.344 ± 0.230                                                                   WTveh-IL-2 versus 4Ekilps-IL-2: *p* \< 0.001                                                                                                                                                                                                                                                                            

  4Ekilps-IL-2: 8.908 ± 0.273                                                                   WTlps-IL-2 versus 4Ekiveh-IL-2: *p* \< 0.001                                                                                                                                                                                                                                                                            

  WTlps-IL-2 versus 4Ekilps-IL-2: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                          

  4Ekiveh-IL-2 versus 4Ekilps-IL-2: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                WTveh-TNFα: 2.728 ± 0.289                                                                               WTveh-TNFα versus WTlps-TNFα: *p* \< 0.001                                                                                                                       *F*~(3,36)~ = 208.7                            

  WTlps-TNFα: 9.028 ± 0.240                                                                     WTveh-TNFα versus 4Ekiveh-TNFα: *p* \< 0.001                                                                                                                                                                                                                                                                            

  4Ekiveh-TNFα: 7.062 ± 0.283                                                                   WTveh-TNFα versus 4Ekilps-TNFα: *p* \< 0.001                                                                                                                                                                                                                                                                            

  4Ekilps-TNFα: 12.80 ± 0.339                                                                   WTlps-TNFα versus 4Ekiveh-TNFα: *p* \< 0.001                                                                                                                                                                                                                                                                            

  WTlps-TNFα versus 4Ekilps-TNFα: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                          

  4Ekiveh-TNFα versus 4Ekilps-TNFα: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                        

  WTveh-IL-6: 1.422 ± 0.096                                                                     WTveh-IL-6 versus WTlps-IL-6: *p* \< 0.001                                                              *F*~(3,36)~ = 102.5                                                                                                                                                                                             

  WTlps-IL-6: 4.467 ± 0.128                                                                     WTveh-IL-6 versus 4Ekiveh-IL-6: *p* \> 0.999                                                                                                                                                                                                                                                                            

  4Ekiveh-IL-6: 1.602 ± 0.126                                                                   WTveh-IL-6 versus 4Ekilps-IL-6: *p* \< 0.001                                                                                                                                                                                                                                                                            

  4Ekilps-IL-6: 4.049 ± 0.240                                                                   WTlps-IL-6 versus 4Ekiveh-IL-6: *p* \< 0.001                                                                                                                                                                                                                                                                            

  WTlps-IL-6 versus 4Ekilps-IL-6: *p* = 0.414                                                                                                                                                                                                                                                                                                                                                                           

  4Ekiveh-IL-6 versus 4Ekilps-IL-6: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                        

  WTveh-IL-1β: 11.32 ± 0.290                                                                    WTveh-IL-1β versus WTlps-IL-1β: *p* \< 0.001                                                            *F*~(3,36)~ = 132.1                                                                                                                                                                                             

  WTlps-IL-1β: 27.47: 27.47 ± 0.687                                                             WTveh-IL-1β versus 4Ekiveh-IL-1β: *p* \> 0.999                                                                                                                                                                                                                                                                          

  4Ekiveh-IL-1β: 11.03 ± 0.830                                                                  WTveh-IL-1β versus 4Ekilps-IL-1β: *p* \< 0.001                                                                                                                                                                                                                                                                          

  4Ekilps-IL-1β: 25.24 ± 1.007                                                                  WTlps-IL-1β versus 4Ekiveh-IL-1β: *p* \< 0.001                                                                                                                                                                                                                                                                          

  WTlps-IL-1β versus 4Ekilps-IL-1β: *p* = 0.176                                                                                                                                                                                                                                                                                                                                                                         

  4Ekiveh-IL-1β versus 4Ekilps-IL-1β: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                      

  WTveh-IL-10: 0.376 ± 0.016                                                                    WTveh-IL-10 versus WTlps-IL-10: *p* \< 0.001                                                            *F*~(3,36)~ = 135.9                                                                                                                                                                                             

  WTlps-IL-10: 1.234 ± 0.050                                                                    WTveh-IL-10 versus 4Ekiveh-IL-10: *p* \> 0.999                                                                                                                                                                                                                                                                          

  4Ekiveh-IL-10: 0.397 ± 0.028                                                                  WTveh-IL-10 versus 4Ekilps-IL-10: *p* \< 0.001                                                                                                                                                                                                                                                                          

  4Ekilps-IL-10: 1.222 ± 0.057                                                                  WTlps-IL-10 versus 4Ekiveh-IL-10: *p* \< 0.001                                                                                                                                                                                                                                                                          

  WTlps-IL-10 versus 4Ekilps-IL-10: *p* = 0.414                                                                                                                                                                                                                                                                                                                                                                         

  4Ekiveh-IL-10 versus 4Ekilps-IL-10: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                      

  Student\'s *t* test                                                                           WT-serotonin: 558.9 ± 22.96                                                                             *p* \< 0.001                                 Concentration (pg/mg protein)                                               WT (20), 4Eki (20)                      *t* = 4.025; df = 38                           [3](#F3){ref-type="fig"}*B*

  4Eki-serotonin: 431.9 ± 21.64                                                                                                                                                                                                                                                                                                                                                                                         

  One-way ANOVA with Bonferroni\'s post hoc                                                     Iba-1: WTveh: 1.141 ± 0.1125, WTlps: 4.214 ± 0.2336, 4Ekiveh: 2.686 ± 0.2241, 4Ekilps: 6.315 ± 0.4868   WTveh versus WTlps: *p* \< 0.001             Concentration (pg/mg protein)                                               WT (10), 4Eki (10)                      *F*~(3,36)~ = 55.02                            [3](#F3){ref-type="fig"}*C*

  WTveh versus 4Ekiveh: *p* = 0.0047                                                                                                                                                                                                                                                                                                                                                                                    

  WTveh versus 4Ekilps: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                                    

  WTlps versus 4Ekiveh: *p* = 0.0053                                                                                                                                                                                                                                                                                                                                                                                    

  WTlps versus 4Ekilps: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                                    

  4Ekiveh versus 4Ekilps: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                                  

  Student\'s *t* test                                                                           WT: 83.05 ± 10.00                                                                                       *p* = 0.015                                  Immobility (s) FST                                                          WT (19), 4Eki (18)                      *t* = 2.548; df = 35                           [4](#F4){ref-type="fig"}*A*

  4Eki: 121.06 ± 11.10                                                                                                                                                                                                                                                                                                                                                                                                  

  WT: 150.50 ± 9.91                                                                             *p* \< 0.001                                                                                            Immobility (s) TST                           WT (14), 4Eki (18)                                                          *t* = 4.761; df = 30                                                                   

  4Eki: 213.39 ± 8.74                                                                                                                                                                                                                                                                                                                                                                                                   

  WT: 71.67 ± 15.24                                                                             *p* = 0.0015                                                                                            Latency to consume food (s) NSF              WT (18), 4Eki (18)                                                          *t* = 3.447; df = 34                                                                   

  4Eki: 143.6 ± 14.23                                                                                                                                                                                                                                                                                                                                                                                                   

  Student\'s *t* test                                                                           WT center: 69.90 ± 5.923                                                                                *p* \< 0.001, *p* \< 0.001                   Time spent in center (s), Time spent in proximity of walls or corners (s)   WT (10), 4Eki (12)                      *t* = 6.792; df = 20, *t* = 10.32; df = 20     

  4Eki center: 25.00 ± 3.492\                                                                                                                                                                                                                                                                                                                                                                                           
  WTwall/corner: 126.9 ± 14.93\                                                                                                                                                                                                                                                                                                                                                                                         
  4Eki wall/corner: 372.7 ± 17.80                                                                                                                                                                                                                                                                                                                                                                                       

  WT: 403.2 ± 17.04                                                                             *p* = 0.801                                                                                             Time spent outside center (s)                                                                                            *t* = 0.199; df = 20                    [4](#F4){ref-type="fig"}*B*                    

  4Eki: 396.8 ± 18.27                                                                                                                                                                                                                                                                                                                                                                                                   

  WT: 4193 ± 125.8                                                                              *p* = 0.830                                                                                             Distance travelled (cm)                                                                                                  *t* = 0.216; df = 20                                                                   

  4Eki: 4233 ± 133.3                                                                                                                                                                                                                                                                                                                                                                                                    

  One-way ANOVA with Bonferroni\'s post hoc                                                     WT: open 98.63 ± 5.227, closed 110.3 ± 5.876\                                                           *p* \< 0.001                                 Time spent in arms (s)                                                      WT (8), 4Eki (8)                        *F*~(3,28)~ = 76.91                            [4](#F4){ref-type="fig"}*C*
                                                                                                4Eki: open 32.38 ± 10.97, closed 189.8 ± 5.786                                                                                                                                                                                                                                                                          

  One-way ANOVA with Bonferroni\'s post hoc                                                     WT veh: 100.3 ± 3.546                                                                                   WT veh versus WT fl: *p* = 0.005             Immobility (s) FST                                                          WT (12), 4Eki (12)                      *F*~(3,44)~ = 25.320                           [5](#F5){ref-type="fig"}*B*

  WT fl: 69.33 ± 4.761                                                                          WT veh versus 4Eki veh: *p* = 0.0079                                                                                                                                                                                                                                                                                    

  4Eki veh: 129.8 ± 7.229                                                                       WT veh versus 4Eki fl: *p* \< 0.001                                                                                                                                                                                                                                                                                     

  4Eki fl: 136.2 ± 7.817                                                                        WT fl versus 4Eki veh: *p* \< 0.001                                                                                                                                                                                                                                                                                     

  WT fl versus 4Eki fl: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                                    

  4Eki veh versus 4Eki fl: *p* \> 0.999                                                                                                                                                                                                                                                                                                                                                                                 

  WT veh: 135.1 ± 11.06                                                                         WT veh versus WTfl: *p* = 0.0081                                                                        Immobility (s) TST                           *F*~(3,44)~ = 73.621                                                        [5](#F5){ref-type="fig"}*C*                                                            

  WT fl: 97.75 ± 6.516                                                                          WT veh versus 4Eki veh: *p* \< 0.001                                                                                                                                                                                                                                                                                    

  4Eki veh: 229.5 ± 6.763                                                                       WT veh versus 4Eki fl: *p* \< 0.001                                                                                                                                                                                                                                                                                     

  4Eki fl: 236.3 ± 7.334                                                                        WT fl versus 4Eki veh: *p* \< 0.001                                                                                                                                                                                                                                                                                     

  WT fl versus 4Eki fl: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                                    

  4Eki veh versus 4Eki fl: *p* \< 0.001                                                                                                                                                                                                                                                                                                                                                                                 

  Student\'s *t* test                                                                           Input: WT:1.090 ± 0.05874, 4Eki: 1.048 ± 0.05977, cap: WT: 0.9975 ± 0.1723, 4EKI: 0.4875 ± 0.1062       Input: *p* = 0.630, cap: *p* = 0.045         rpL13a                                                                      WT (4), 4Eki (4) or, WT (8), 4EKi (8)   Input: *t* = 0.507, cap: *t* = 2.520; df = 6   [6](#F6){ref-type="fig"}

                                                                                                Input: WT:1.248 ± 0.335, 4Eki: 1.440 ± 0.583, cap: WT: 1.003 ± 0.142, 4Eki: 0.325 ± 0.075               Input: *p* = 0.784, cap: *p* = 0.005         eIF4A1                                                                                                              Input: *t* = 0.285, cap: *t* = 4.196; df = 6   

  1.088 ± 0.08499, 0.9525 ± 0.05977, cap: WT: 0.997 ± 0.222, 4Eki: 0.9175 ± 0.199               Input: *p* = 0.241, cap: *p* = 0.798                                                                    eIF4E                                        Input: *t* = 1.299 , cap: *t* = 0.267; df = 6                                                                                                                      

  Input: WT:1.145 ± 0.078, 4Eki: 0.905 ± 0.099 , cap: WT: 1.002 ± 0.149, 4Eki: 0.830 ± 0.218    Input: *p* = 0.106, cap: *p* = 0.544                                                                    eIF4G                                        Input: *t* = 1.894, cap: *t* = 0.642; df = 6                                                                                                                       

  Input: WT:1.025 ± 0.108, 4Eki: 0.98 ± 0.108 , cap: WT: 1.002 ± 0.185, 4Eki:0.10.2 ± 0.185     Input: *p* = 0.839, cap: *p* = 0.382                                                                    Eprs                                         Input: *t* = 0.206, cap: *t* = 1.063; df = 14                                                                                                                      

  Input: WT: 0.998 ± 0.091, 4Eki: 0.901 ± 0.091 , cap: WT: 0.998 ± 0.254, 4Eki: 0.775 ± 0.254   Input: *p* = 0.106, cap: *p* = 0.544                                                                    Gapdh                                        Input: *t* = 1.060, cap: *t* = 0.880; df = 14                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results
=======

Loss of eIF4E phosphorylation does not affect hippocampal learning, memory, or L-LTP
------------------------------------------------------------------------------------

eIF4E is highly expressed throughout the hippocampal formation ([Fig. 1](#F1){ref-type="fig"}*A*). To examine the role of eIF4E Ser209 phosphorylation in the hippocampus, we subjected WT and *Eif4e^Ser209Ala^* phospho-mutant knock-in mice (*4Eki*) ([@B22]) to hippocampus-dependent behavioral tests. First, we examined spatial memory in the MWM ([Fig. 1](#F1){ref-type="fig"}*B*). *4Eki* mice were indistinguishable from WT mice during the learning phase, as they displayed comparable latency to find the hidden platform, and comparable numbers of platform crossings ([Fig. 1](#F1){ref-type="fig"}*B*). Quadrant occupancy during the probe test on day 6 was not different between WT and *4Eki* mice ([Fig. 1](#F1){ref-type="fig"}*B*). Second, we assessed long-term contextual fear memory using a CFC task ([Fig. 1](#F1){ref-type="fig"}*C*). In line with MWM data, contextual memory was intact in *4Eki* mice, as the percentage of freezing in response to context was not different from WT mice ([Fig. 1](#F1){ref-type="fig"}*C*). These data indicate that hippocampus-dependent contextual memory is not affected by the lack of eIF4E phosphorylation.

![Intact spatial learning and memory, contextual fear memory, and L-LTP in *4Eki* mice. ***A***, Representative confocal images of immunofluorescent staining of WT dorsal hippocampi with antibodies against total and phospho-Ser209 eIF4E. Scale bar, 100 μm. ***B***, MWM task. Left, Graphic depiction of experimental design; latency (seconds) to find hidden platform during experimental days. Right, Platform crossings and quadrant occupancy during probe test (WT, *n* = 7; *4Eki*, *n* = 8). \*\*\**p* \< 0.001 (repeated-measures ANOVA with Tukey\'s *post hoc*). ***C***, CFC in *4Eki* mice. Percentage freezing 24 h after initial shock (WT, *n* = 8; *4Eki*, *n* = 8). ***D***, CA1 L-LTP recordings in *4Eki* mice. Normalized fEPSP slope over time (min) for 240 min. ***E***, Summary quantification of percentage potentiation for L-LTP. (Student\'s *t* test).](zns9991805500001){#F1}

We next measured LTP in CA1 hippocampal area, a form of plasticity that is MAPK- and protein synthesis-dependent ([@B18]; [@B14]). Four trains of high-frequency stimulation (4HFS) of the Schaffer collateral-CA1 synapses elicited long-lasting potentiation of fEPSPs in WT slices ([Fig. 1](#F1){ref-type="fig"}*D*). The 4HFS-induced potentiation was not different in slices prepared from *4Eki* mice compared with WT ([Fig. 1](#F1){ref-type="fig"}*D*,*E*). Together, mutating the single phosphorylation site on eIF4E (which lies downstream of the MAPK/ERK/MNK pathway and upstream of translation initiation) does not impair hippocampus-dependent learning and memory, or CA1 hippocampal L-LTP.

Phospho-eIF4E regulates the translation of a subset of mRNAs
------------------------------------------------------------

Given the unexpected result that eIF4E phosphorylation is not required for key forms of hippocampal memory formation and synaptic plasticity, we sought to elucidate the role of phospho-eIF4E in the brain by performing genome-wide analysis of mRNA translation, with the ribosome profiling methodology ([@B30]). Using forebrain tissue (including hippocampus) from WT and *4Eki* mice, we generated libraries for RNA sequencing from randomly fragmented total RNA (a proxy for transcription) and from ribosome-protected footprints following RNase digestion (a proxy for translation), to measure the translational efficiency of mRNAs ([Fig. 2](#F2){ref-type="fig"}*A*). We did not observe a significant change in global translation or transcription in 4Eki forebrain ([Fig. 2](#F2){ref-type="fig"}*B*), in accordance with previous reports ([@B22]). The high quality of footprint and mRNA libraries is evidenced by the following: (1) the *r*^2^ of RPKM between replicates, which is \>0.99 for both footprints and total mRNA ([Fig. 2-1](#fig2-1){ref-type="supplementary-material"}*A*); (2) the canonical distribution of footprint size (28--32 nt) and of read distribution within the 3 frames ([Fig. 2-1](#fig2-1){ref-type="supplementary-material"}*B*); and (3) principal components and clustering analysis of replicates ([Fig. 2-1](#fig2-1){ref-type="supplementary-material"}*C*,*D*). We found that, even though the Ser209Ala mutation does not affect global translation, it regulates the translational efficiency of a subset of mRNAs ([Fig. 2](#F2){ref-type="fig"}*B*). The translation of 651 mRNAs was significantly downregulated (*4Eki*/WT ratio ≤0.75, *p* \< 0.05), whereas the translation of 52 mRNAs was significantly upregulated (*4Eki*/WT ratio ≥1.5, *p* \< 0.05) ([Fig. 2](#F2){ref-type="fig"}*B*).

![Ribosome profiling reveals preferential translation of a subset of mRNAs in the forebrain of *4Eki* mice. ***A***, Experimental design to assess genome-wide translational efficiency of mRNAs using ribosome profiling in whole brain tissue from WT and *4Eki* mice. ***B***, log~2~ TE Plot showing translationally upregulated (red), downregulated (blue), and control (gray) mRNAs in *4Eki* versus WT libraries (*p* \< 0.05 and 0.75 ≥ TE ratio ≤ 1.5). Gray represents unchanged mRNAs; *n* = 2 for footprints and mRNA. ***C***, UTR analysis using RegRNA in downregulated (651; blue), upregulated (52; red), and control (325; gray) mRNAs in *4Eki*, compared with WT. Percentage of genes containing one or more of the depicted RNA sequence elements in 5′- or 3′-UTR. ^\#^Categories in downregulated or upregulated mRNAs, which are underrepresented compared with control mRNAs. ([Fig. 2-1](#fig2-1){ref-type="supplementary-material"}***A***, [Fig. 2-1](#fig2-1){ref-type="supplementary-material"}***B***, [Fig. 2-1](#fig2-1){ref-type="supplementary-material"}***C*,*D***). ***D***, Length and GC content analysis of differentially translated mRNAs. Length (bp) or percentage of GC content is displayed for 5′-UTR (left) or 3′-UTR (right). ^\#^*p* \< 0.05 difference from all other categories (one-way ANOVA with Tukey\'s *post hoc*); all other multiple comparisons between groups are not significant. ***E***, Gene ontology analysis of 651 downregulated genes; plots for biological process, molecular function, and cellular component with number of genes in each category. *p* values next to each category are shown. ***F***, KEGG pathway analysis for downregulated genes. ***G***, Major genes downregulated in ribosome profiling organized in two categories: pituitary hormone genes and ECM genes with *p* value and FDR. ***H***, Gene ontology analysis of 52 upregulated genes; plots for cellular component with number of genes in each category and *p* values and KEGG pathway analysis. Major genes upregulated in ribosome profiling organized in two categories: serotonin and ribosomal proteins; *p* value and FDR are shown for downregulated and upregulated genes.](zns9991805500002){#F2}
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**Reproducibility and quality of RPF data. A.** Reproducibility plots for WT and 4Eki sequenced libraries (for replicates of total mRNA and footprints (grey corresponds to data points with \<128 reads). **B.** Frequency and length of mapped reads and fraction of reads within start codon window for the 3 frames for total mRNA and footprint libraries. Principle components analysis (PCA) and clustering analysis dendrogram for **C.** Translation and **D.** Transcription for the two biological replicates used for WT (WT1, WT2) or 4Eki (KI1, KI2). Download Figure 2-1, TIF file

Because UTRs harbor sequence elements, which may explain changes in translational efficiency, we analyzed *4Eki*-sensitive mRNA 5′- and 3′-UTRs, along with 325 mRNAs (control group) that were not regulated by phospho-eIF4E in our ribosome profiling experiment ([Fig. 2](#F2){ref-type="fig"}*C*), using the RegRNA suite ([@B29]). The 5′-UTRs of downregulated, but not upregulated, mRNAs contain a reduced number of upstream open reading frames (uORFs), internal ribosome entry sites (IRESs), and terminal oligopyrimidine tract (TOP) compared with the control group ([Fig. 2](#F2){ref-type="fig"}*C*). The 3′-UTRs of downregulated mRNAs, but not of upregulated, harbor a significantly reduced number of GAIT elements, compared with the control and upregulated mRNA groups ([Fig. 2](#F2){ref-type="fig"}*C*). The incidence of cytoplasmic polyadenylation elements (CPEs), both in downregulated and upregulated mRNAs, is reduced compared with the control group ([Fig. 2](#F2){ref-type="fig"}*C*). These data suggest that the incidence of 5′ uORF, IRES, and 3′ GAIT elements in the UTRs of *4Eki*-downregulated mRNAs, compared with upregulated and control groups, may reveal a previously unidentified phospho-eIF4E-dependent translational control mechanism in the brain. Notably, we analyzed the length and guanine-cytosine content (GC%) in UTRs and detected a significant increase in the length of 5′-UTRs in downregulated mRNAs, compared with other mRNA groups, but not for GC% ([Fig. 2](#F2){ref-type="fig"}*D*). 3′-UTR length or GC% was not different between gene groups ([Fig. 2](#F2){ref-type="fig"}*D*).

To further understand the translational control mechanisms downstream of phospho-eIF4E in the brain, we performed gene ontology analysis for the downregulated ([Fig. 2](#F2){ref-type="fig"}*E--G*) and upregulated genes ([Fig. 2](#F2){ref-type="fig"}*H*). For the significantly downregulated genes group, we identified several biological process, molecular function, and cellular component categories (*p* \< 0.05; [Fig. 2](#F2){ref-type="fig"}*E*,*F*). Some key categories include response to stress, extracellular organization and ECM, biological adhesion, and defense response, whereas some key pathways were also identified (e.g., PI3K-Akt signaling pathway and ECM-receptor interaction) ([Fig. 2](#F2){ref-type="fig"}*E*,*F*). Some of the major gene groups that are downregulated in *4Eki* forebrain are genes encoding for pituitary hormones and ECM genes ([Fig. 2](#F2){ref-type="fig"}*G*), including *Mmp9*, which we have previously shown to be crucial for reversing behavioral, anatomical, and biochemical deficits in *Fmr1*^−/*y*^ mice ([@B22]; [@B21]). Conversely, in the upregulated genes group, the most enriched gene ontology category and pathway is the ribosome, whereas two major gene groups that are upregulated translationally include genes in the serotonin pathway and ribosomal protein coding genes ([Fig. 2](#F2){ref-type="fig"}*H*). Together, these data suggest that, downstream of MAPK/ERK, eIF4E phosphorylation does not affect global translation but preferentially regulates the synthesis of certain proteins by modulating their mRNA translation via 5′- and 3′-UTR elements, such as GAIT. Importantly, the list of regulated mRNAs points toward a role of phospho-eIF4E in ECM regulation, pituitary hormones, the serotonin pathway, and ribosomal proteins.

Exaggerated inflammatory response and reduced serotonin levels in *4Eki* brain
------------------------------------------------------------------------------

To further investigate the role of phospho-eIF4E in the brain, we proceeded to identify potential phenotypic changes, which could result from the aberrant translation of specific categories of mRNAs in *4Eki* brain ([Fig. 2](#F2){ref-type="fig"}). We hypothesized that inflammatory responses may be altered in *4Eki* mice, given the known link of phospho-eIF4E and eIF4E to innate immunity ([@B8]; [@B25]) and because many inflammatory mRNAs harbor GAIT elements in their 3′-UTRs ([@B44]), similarly to our upregulated mRNAs ([Fig. 2](#F2){ref-type="fig"}*C*). The mRNA 3′-UTR GAIT element is a "gatekeeper" of inflammatory gene expression ([@B44]). Therefore, we set out to measure inflammatory reponses in forebrain lysates using quantitative ELISA for 6 major cytokines. Treatment of *4Eki* mice with LPS (strain O111:B4, 5 mg/kg, intraperitoneally) led to a significantly higher expression of distinct cytokines 4 h after injection in *4Eki* mouse forebrain, compared with WT ([Fig. 3](#F3){ref-type="fig"}*A*). In *4Eki* brain, we detected a significant increase in IL-2 and TNFα expression, both at baseline and following LPS stimulation, compared with WT ([Fig. 3](#F3){ref-type="fig"}*A*). For IFNγ, we detected a significant upregulation in *4Eki* versus WT only following LPS stimulation, but not at baseline ([Fig. 3](#F3){ref-type="fig"}*A*), whereas for IL-6, IL-10, and IL-1B there were no differences between *4Eki* and WT mice ([Fig. 3](#F3){ref-type="fig"}*A*). Interestingly, IL-2, TNFα, and IFNγ are produced by Th1-type T-cell subsets, whereas IL-6, IL-10, and IL-1B by Th2-type ([@B51]).

![Exaggerated inflammatory responses and reduced serotonin levels in *4Eki* brain. ***A***, Quantitative ELISA for 6 mouse inflammatory cytokines in WT and *4Eki* forebrains (*n* = 10 for each genotype). Blue represents Th1 cytokines. Gray represents Th2 cytokines. ***B***, Left, Serotonin pathway genes upregulated in *4Eki* brain (red). Quantitative ELISA for serotonin (5-HT) in WT and *4Eki* forebrains (*n* = 20 for each genotype). Normalized concentration (pg/mg) is shown for all experiments. ***C***, Quantitative ELISA for Iba-1, a marker of activated microglia (*n* = 10 for each genotype). ***A***, ***C***, \*\*\**p* \< 0.001 (one-way ANOVA with Bonferroni\'s *post hoc*). \*\**p* \< 0.01 (one-way ANOVA with Bonferroni\'s *post hoc*). ***B***, \*\*\**p* \< 0.001 (Student\'s *t* test).](zns9991805500003){#F3}

We further reasoned that the translational upregulation of the serotonin uptake receptor (Slc6a4) and the enzyme tryptophan hydroxylase (Tph2) ([Fig. 2](#F2){ref-type="fig"}*H*) would be accompanied by changes in the amount of serotonin in the 4Eki brain, as previously shown ([@B7]; [@B62]; [@B61]). Using quantitative ELISA, we measured a decrease in tissue levels of serotonin in 4Eki forebrain, compared with WT ([Fig. 3](#F3){ref-type="fig"}*B*). Furthermore, we also detected an increase in Iba-1 at baseline and following LPS stimulation in *4Eki* mice, compared with WT ([Fig. 3](#F3){ref-type="fig"}*C*), suggesting that microglia are activated in the Ser209Ala mouse model.

Together, these data suggest that the elaborate translational landscape downstream of phospho-eIF4E elicits complex alterations in the brain consisting of changes in inflammatory responses and serotonergic function.

Depression and anxiety-like behaviors in *4Eki* mice
----------------------------------------------------

There is a strong link between serotonin, pituitary hormones such as prolactin, and depression/anxiety ([@B3]; [@B61]). Moreover, phospho-eIF4E is upregulated in response to chronic treatment with the SSRI antidepressant fluoxetine ([@B11]). Thus, we reasoned that the pathways regulated by eIF4E phosphorylation could be linked to depression. To test this hypothesis, we subjected WT and *4Eki* mice to the FST and TST, which have been shown to model depression-like behaviors in mice by assessing passive immobility after a few minutes of futile struggling ([@B10]). *4Eki* mice remained immobile longer than WT mice in both FST and TST tests, suggesting a depression-like phenotype ([Fig. 4](#F4){ref-type="fig"}*A*). To further study the depression-like phenotype of the *4Eki* mice, we used the NSF, which measures the latency of a mouse to start feeding in a novel environment, following 24 h food restriction. It has been extensively shown that mouse models of depression display increased latencies to initiate feeding in the NSF test (hyponeophagia) ([@B12]), whereas chronic antidepressants were shown to reduce this latency ([@B5]). *4Eki* mice required a significantly higher amount of time per session to initiate feeding in NSF, compared with WT ([Fig. 4](#F4){ref-type="fig"}*A*). Furthermore, we examined *4Eki* mice for anxiety-like behaviors using the open field test ([Fig. 4](#F4){ref-type="fig"}*B*). *4Eki* mice spent significantly less time in the central region of the arena and significantly more time in proximity to walls or corners, suggesting elevated anxiety; however, the time spent outside the central square and total distance traveled were similar between *4Eki* and WT mice, indicating that locomotion was not affected ([Fig. 4](#F4){ref-type="fig"}*B*). In line with these findings, we detected an anxiety-like phenotype in *4Eki* mice subjected to the EPM ([Fig. 4](#F4){ref-type="fig"}*C*). *4Eki* mice, compared with WT, spend significantly less time in the open and significantly more time in the closed arms of the maze ([Fig. 4](#F4){ref-type="fig"}*C*). In summary, these data indicate that *4Eki* mice display anxiety and depression-like behaviors.

![Depression and anxiety-like behaviors in *4Eki* mice. ***A***, Immobility time (seconds) as an indicator of depression-like behaviors in FST (left) and TST (middle) in WT(n = 14) and *4Eki* (n = 18) mice. NSF (right), latency to start feeding in a novel environment, as a proxy for depression/anxiety-mediated hypophagia in WT and *4Eki* (*n* = 18 each) mice. ***B***, Open field exploration test (OF) in WT (*n* = 10) and *4Eki* (*n* = 12) mice, as a measure of anxiety. Time (seconds) spent in the center square, in proximity of corners or walls, or outside the center square and total distance traveled. ***A***, ***B***, \**p* \< 0.05 (Student\'s *t* test). \*\**p* \< 0.01 (Student\'s *t* test). \*\*\**p* \< 0.001 (Student\'s *t* test). ***C***, EPM in WT (*n* = 8) and *4Eki* (*n* = 8) mice, as a measure of anxiety. Time (seconds) spent in the open or closed arms of the elevated maze. ***C***, \*\*\**p* \< 0.001 (one-way ANOVA with Bonferroni\'s *post hoc*).](zns9991805500004){#F4}

Chronic fluoxetine treatment does not rescue depression-like behaviors in *4Eki* mice
-------------------------------------------------------------------------------------

Chronic fluoxetine treatment induced phosphorylation of eIF4E at Ser209 ([@B11]) and alleviated depression-like phenotypes in mice ([@B13]). Thus, we hypothesized that the chronic antidepressant effect of fluoxetine is mediated via stimulation of eIF4E phosphorylation ([Fig. 5](#F5){ref-type="fig"}*A*). Chronic (21 d) intraperitoneal treatment of WT mice with fluoxetine (10 mg/kg/d) led to an ∼25% decrease in immobility in both FST and TST tests ([Fig. 5](#F5){ref-type="fig"}*A--C*), which is in accordance with previous reports ([@B13]). Strikingly, in *4Eki* mice, fluoxetine did not affect immobility in either test ([Fig. 5](#F5){ref-type="fig"}*B*,*C*), indicating that phospho-eIF4E is required for the antidepressant action of fluoxetine.

![Chronic fluoxetine intraperitoneal treatment does not reverse depression-like behaviors in *4Eki* mice. ***A***, Outline of chronic fluoxetine regimen. Intraperitoneal injection of 10 mg/kg/d for 21 d reduces immobility time (seconds) in WT (*n* = 12) but not *4Eki* (*n* = 12) mice. ***B***, FST. ***C***, TST. \*\**p* \< 0.01, \*\*\**p* \< 0.001 (one-way ANOVA with Bonferroni\'s post-hoc).](zns9991805500005){#F5}

Reduced cap binding of rpL13a and eIF4A1 in *4Eki* mice
-------------------------------------------------------

UTR analysis of differentially translated mRNAs in the forebrain of *4Eki* mice revealed that upregulated mRNAs display a higher incidence of 3′-UTR GAIT elements, compared with downregulated mRNAs ([Fig. 2](#F2){ref-type="fig"}*C*). GAIT elements repress translation by recruiting a complex of proteins (GAIT complex: rpL13a, Eprs and Gapdh) on mRNA 3′-UTR ([@B44]). Subsequently, the GAIT complex is bridged to the 5′-UTR cap-bound eIF4F, via direct interaction of the GAIT complex protein rpL13a and eIF4G ([Fig. 6](#F6){ref-type="fig"}*A*). Reduced binding of GAIT complexes to eIF4F, when phospho-eIF4E is depleted, could explain the upregulation of a small subset of mRNAs containing 3′-UTR GAIT elements (*n* = 52; [Fig. 2](#F2){ref-type="fig"}*C*,*H*) via translational disinhibition. Likewise, mRNAs with low incidence of 3′-UTR GAIT elements should not be affected to the same extent by this regulatory mechanism ([Fig. 2](#F2){ref-type="fig"}*C*,*G*). To test this hypothesis, we performed cap-column pulldown of forebrain lysates using m^7^GDP agarose beads, followed by immunoblotting of cap-bound and of whole lysates as a control ([Fig. 6](#F6){ref-type="fig"}*A*). By probing for key eIF4F proteins (eIF4E, eIF4G, and eIF4A), we can detect changes in their binding to the mRNA cap. By probing for the GAIT complex proteins rpL13a, Eprs, and Gapdh in cap-bound fractions, we can assess changes in GAIT complex-eIF4F binding; importantly, rpL13a bridges GAIT to eIF4F ([Fig. 6](#F6){ref-type="fig"}*A*). We detected in *4Eki* forebrain lysates, decreased cap binding of rpL13a and of the eIF4F helicase eIF4A1, whereas eIF4E, eIF4G, Eprs, and Gapdh cap binding was not altered ([Fig. 6](#F6){ref-type="fig"}*A*,*B*). Eprs and Gapdh cap binding was not altered in *4Eki* mice, which could be due to the fact that these proteins may interact with eIF4F as monomers, outside of the GAIT complex ([@B52]). This is not the case for ribosomal protein rpL13a, as its main extraribosomal function is to bridge GAIT to eIF4F and mediate translational repression ([@B34]).

![Altered cap binding of GAIT complex protein rpL13a and eIF4A1 in *4Eki* brains. ***A***, Cap-column (m^7^GDP) pulldown from forebrain lysates (WT and *4Eki*; *n* = 4 per genotype or *n* = 8 for Eprs, Gapdh). Left, Diagram of the closed loop model of translation depicting binding of repressive 3′-UTR GAIT elements to 5′-UTR cap-bound eIF4F complex, via rpL13a and below a depiction of a cap-column agarose bead. Representative immunoblot images from cap-bound and input lysates probed with antibodies against the indicated proteins (eIF4E, eIF4G, eIF4A1 rpL13a, Eprs, and Gapdh; β-actin is the loading control). ***B***, Quantification of protein expression from input (5%) and cap-bound lysates. Protein expression (arbitrary units) normalized to input protein expression for cap-bound lysates and to β-actin for input lysates. \**p* \< 0.05 (Student\'s *t* test).](zns9991805500006){#F6}

Thus, ablation of the single phosphorylation site on eIF4E engenders selective translation of a subset of mRNAs, conceivably through altered cap binding and translation initiation mediated by mRNA UTR elements, such as GAIT ([Fig. 7](#F7){ref-type="fig"}*A*).

![Depletion of eIF4E phosphorylation engenders inflammatory and depression-like phenotypes via selective translational control of a subset of mRNAs. ***A***, Ablation of the single phosphorylation site on eIF4E (Ser209→Ala) does not affect global protein synthesis, but rather the translation of a subset of mRNAs harboring GAIT elements, which engenders a depression-like phenotype in *4Eki* mice. *4Eki* mice also display increased expression of inflammatory cytokines, which could be linked to disinhibition of GAIT translational repression and possibly to depression-like phenotypes. Altered cap binding of the helicase eIF4A1 and/or of the GAIT complex protein rpL13a could be the mechanism underlying altered translation initiation following depletion of Ser209 eIF4E phosphorylation. ***B***, The SSRI fluoxetine requires eIF4E phosphorylation to exert its antidepressant action. ***C***, Phosphorylation of eIF4E promotes anti-inflammatory and antidepressant pathways.](zns9991805500007){#F7}

Discussion
==========

We show that phospho-eIF4E plays a previously unidentified role in the brain, whereby its depletion engenders depression-like behaviors ([Fig. 4](#F4){ref-type="fig"}) and resistance to the chronic antidepressant action of the SSRI fluoxetine ([Fig. 7](#F7){ref-type="fig"}*B*). We also show that eIF4E phosphorylation is not required for major forms of hippocampal learning and memory and L-LTP ([Fig. 1](#F1){ref-type="fig"}). We further demonstrate that a potential underlying mechanism involves the selective mRNA translation of GAIT element-containing mRNAs and of mRNAs harboring long 5′-UTRs ([Fig. 7](#F7){ref-type="fig"}*A*). This multifaceted translational control pathway in 4Eki mouse brain may be responsible for the observed changes in inflammatory responses, serotonin levels, pituitary hormones, and the ECM ([Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}), which could underlie the depression-like behaviors ([Fig. 4](#F4){ref-type="fig"}) and the resistance to the antidepressant action of fluoxetine ([Fig. 5](#F5){ref-type="fig"}).

Translational control by the MAPK pathway was shown to be crucial for hippocampal synaptic plasticity, learning, and memory ([@B35]). Contrary to the prediction that ablation of phospho-Ser209 in eIF4E would recapitulate MAPK deletion phenotypes, we found that in Ser209Ala mutant mice (*4Eki*), hippocampal learning and memory, as well as a major form of long-term synaptic plasticity (L-LTP) are intact ([Fig. 1](#F1){ref-type="fig"}). It is generally believed that L-LTP and long-term memory require new protein synthesis ([@B18]). We show, for the first time, that the phosphorylation of eIF4E downstream of MAPK/ERK is not required for L-LTP ([Fig. 1](#F1){ref-type="fig"}*D*). We cannot rule out the possibility that phospho-eIF4E is essential for other forms of synaptic plasticity ([@B45]) or that it is important in brain regions outside the hippocampus. We also cannot exclude the presence of compensatory mechanisms in *4Eki* mice (e.g., mTORC1 activation), which could substitute for the loss of eIF4E phosphorylation. Alternatively, MAPK/ERK may regulate hippocampal synaptic plasticity, learning, and memory by phosphorylating other translation initiation factors.

Ribosome profiling in the brain of 4Eki mice revealed translational downregulation of several mRNAs (encoding for ECM genes and pituitary hormones) ([Fig. 2](#F2){ref-type="fig"}*G*). eIF4E phosphorylation was previously suggested to control cancer metastasis ([@B19]; [@B50]), by controlling ECM function and in particular the translation of MMPs, such as MMP-9 ([@B19]; [@B22]; [@B21]). Thus, it will be important to further investigate the role of ECM regulation downstream of phospho-eIF4E in the brain. Control of pituitary mRNA translation is a novel function assigned to phospho-eIF4E; and apart from its link to depression, it will be important to examine its potential links to other neuropsychiatric or neurodevelopmental disorders or cancer (e.g., pituitary adenomas). On the other hand, serotonin pathway and ribosomal protein coding genes are upregulated in *4Eki* brain ([Fig. 2](#F2){ref-type="fig"}*H*). Given the interplay between the hypothalamic-pituitary-adrenal axis, serotonin and dopamine ([@B23]; [@B28]), we are proposing a new translational control pathway (via phospho-eIF4E) implicated in this regulation, which may be modulated pharmacologically. The ribosome profiling strategy was invaluable in identifying phospho-eIF4E-regulated transcripts, and subsequently phenotypic changes. However, it did not reveal cell-type-specific alterations in translation, which could further elucidate the mechanisms underlying the depression-like phenotypes observed in *4Eki* mice. Given that we detected inflammatory changes in Iba-1 (a marker of microglia activation; [Fig. 3](#F3){ref-type="fig"}*C*), it would be imperative to perform cell-type-specific profiling of translation in neuronal and non-neuronal cells (e.g., microglia) using methodologies, such as TRAP ([@B24]). Nevertheless, our translational profiling revealed that ablation of eIF4E phosphorylation downregulates the translation of a large subset of mRNAs, without affecting global translation, and upregulates the translation of a very small subset of mRNAs ([Fig. 2](#F2){ref-type="fig"}). Overall, these data suggest that eIF4E phosphorylation promotes translation initiation.

Proinflammation programs in 4Eki mice ([Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}) could be causal for the depression-like behaviors observed in these mice ([Fig. 4](#F4){ref-type="fig"}). Depression is frequently comorbid with many inflammatory illnesses ([@B40]), while antidepressants can decrease inflammatory responses ([@B59]), suggesting that depression and inflammation are closely linked. Conceivably, proinflammatory responses in *4Eki* brain could be linked to depression-like behaviors: (1) by GAIT mRNA translational disinhibition ([Figs. 2](#F2){ref-type="fig"}, [6](#F6){ref-type="fig"}), linked to inflammation ([Fig. 3](#F3){ref-type="fig"}); (2) through the known link of eIF4E and enhanced Type I IFN production ([@B8]); or (3) as a result of enhanced activity of NF-κB following translational downregulation of its inhibitor IκBα in *4Eki* ([@B25]). Indeed, we observed a baseline and LPS-stimulated upregulation of Th1-type ([@B51]) cytokines: IFNγ, TNFα, and IL-2 ([Fig. 3](#F3){ref-type="fig"}*A*). Notably, a shift in the Th1/Th2 balance in favor of Th1 cytokine expression cytokines was shown to be linked to depression ([@B20]; [@B41]) and other neuropsychiatric disorders ([@B26]).

We identified exacerbated immobility/"despair-like," hyponeophagy and anxiety-like behaviors in *4Eki* mice, which are reminiscent of human depression/anxiety ([Fig. 4](#F4){ref-type="fig"}). The link between phospho-eIF4E and depression is further strengthened by the fact that chronic fluoxetine treatment (10 mg/kg for 21 d) requires eIF4E phosphorylation to exert its antidepressant effect ([Fig. 5](#F5){ref-type="fig"}). Fluoxetine also recruits other pathways upstream of the translation initiation machinery, such as mTORC1 ([@B39]). While the connection between inflammation and depression is still under investigation, our data highlight a new translational control pathway, which may underlie the chronic antidepressant action of SSRIs and could be exploited to design novel antidepressants by boosting eIF4E phosphorylation ([Fig. 7](#F7){ref-type="fig"}*C*).

In addition, we have further elucidated the mechanism of translational control downstream of phospho-eIF4E by identifying key 5′- and 3′-UTR sequence elements, and changes in signaling, which may confer specificity to phospho-eIF4E translational control ([Fig. 2](#F2){ref-type="fig"}*C*). From the UTR analysis, we identified an underrepresentation of uORF, IRES, TOP, CPE, and GAIT elements in *4Eki*-downregulated mRNAs. CPE elements may regulate translation of *4Eki*-sensitive mRNAs, which could be explained through changes in the activity of poly(A)-binding protein, which prompts mRNA circularization by bridging 5′ eIF4G to 3′ poly(A) tail ([@B55]). Furthermore, translation of uORF-containing mRNAs is regulated by the eIF2α pathway in the brain ([@B9]). Even though we did not detect any changes in eIF2α phosphorylation in *4Eki* mice (data not shown), mTORC1 may regulate uORF-containing mRNA translation ([@B54]). Likewise, we did not detect significant changes in IRES translation in *4Eki* mice (data not shown). The translation of TOP mRNAs (e.g., ribosomal protein coding mRNAs) was previously shown to be mTORC1-sensitive ([@B2]; [@B58]), which is in line with our GO analysis ([Fig. 2](#F2){ref-type="fig"}*G*,*H*; KEGG pathways).

The presence of GAIT sequence elements in the 3′-UTR of proinflammatory mRNAs suppresses their translation ([@B43]). A key event in this process is the binding of rpL13a, a core constituent of the GAIT protein complex, to the 5′ cap by direct binding to eIF4G ([@B17]). Genetic depletion of eIF4E Ser209 phosphorylation leads to reduced binding of rpL13a to the 5′ cap ([Fig. 6](#F6){ref-type="fig"}), predicting that in *4Eki* brain there would be translational disinhibition of mRNAs harboring GAIT elements. Indeed, *4Eki*-downregulated mRNAs have a low incidence of 3′-UTR GAIT elements, which could explain why they are not affected by phospho-eIF4E-mediated, GAIT complex-dependent translational disinhibition. This also suggests that downregulation of the 651 mRNAs probably occurs via a different mechanism. Conversely, upregulated mRNAs display a significantly higher incidence of 3′-UTR GAIT elements ([Fig. 2](#F2){ref-type="fig"}*C*). Concomitantly, *4Eki* brains exhibit exaggerated expression of proinflammatory cytokines, which could be explained by GAIT complex-mediated disinhibition of mRNAs coding for cytokines ([Fig. 3](#F3){ref-type="fig"}*A*). Furthermore, cap-pulldown of the helicase eIF4A1 is significantly reduced in *4Eki* forebrain ([Fig. 6](#F6){ref-type="fig"}) and is accompanied by increased length of 5′-UTRs in *4Eki*-downregulated mRNAs, compared with other groups ([Fig. 2](#F2){ref-type="fig"}*D*). Thus, it is possible that phospho-eIF4E requires the helicase eIF4A1 to resolve long 5′-UTRs, which is in accordance with previous reports linking eIF4E to eIF4A1 activity ([@B15]). This mechanism could explain the translational downregulation of the 651 mRNAs. Thus, our ribosome profiling data along with the biochemical investigation of cap complex formation in the brains of *4Eki* mice have revealed potential mechanisms for the observed selective translational control. However, further work is required to build a comprehensive model for the synergistic action of UTR elements, such as GAIT, uORF, IRES, TOP, and CPE, downstream of eIF4E phosphorylation.

In conclusion, phospho-eIF4E-dependent translation of GAIT element-containing mRNAs may constitute a unifying mechanistic explanation as to how dysregulated translational control of specific mRNAs could be causal for inflammation and depression, without affecting general translation.
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